These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17595597)

  • 1. Arformoterol (Brovana) for COPD.
    Med Lett Drugs Ther; 2007 Jul; 49(1264):53-5. PubMed ID: 17595597
    [No Abstract]   [Full Text] [Related]  

  • 2. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formoterol (Perforomist) for COPD.
    Med Lett Drugs Ther; 2007 Nov; 49(1274):94-5. PubMed ID: 18007544
    [No Abstract]   [Full Text] [Related]  

  • 4. Formoterol therapy for chronic obstructive pulmonary disease: a review of the literature.
    Friedman M; Della Cioppa G; Kottakis J
    Pharmacotherapy; 2002 Sep; 22(9):1129-39. PubMed ID: 12222549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formoterol dry-powder inhaler for the treatment of asthma and chronic obstructive pulmonary disease.
    Prenner BM
    Expert Opin Pharmacother; 2007 Dec; 8(17):3069-84. PubMed ID: 18001266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arformoterol tartrate in the treatment of COPD.
    Cazzola M; Hanania NA; Matera MG
    Expert Rev Respir Med; 2010 Apr; 4(2):155-62. PubMed ID: 20406080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
    Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT
    Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease.
    Berger WE; Nadel JA
    Respir Med; 2008 Feb; 102(2):173-88. PubMed ID: 18023995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases.
    Sin DD; Man SF
    Eur J Pharmacol; 2006 Mar; 533(1-3):28-35. PubMed ID: 16457807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nebulized arformoterol: what is its place in the management of COPD?
    Miles MC; Donohue JF; Ohar JA
    Ther Adv Respir Dis; 2013 Apr; 7(2):81-6. PubMed ID: 23147985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Agonists of beta2 adrenergic receptor in the therapy of obstructive diseases].
    Płusa T
    Pol Merkur Lekarski; 2010 Jan; 28(163):8-12. PubMed ID: 20369715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical pharmacology of a new specific adrenergic beta bronchodilator].
    Curti PC
    Int J Clin Pharmacol; 1974 Jun; 9(4):305-13. PubMed ID: 4153546
    [No Abstract]   [Full Text] [Related]  

  • 13. [Comments of the German Airway League and the German Respiratory Society to the US Food and Drug Administration (FDA)'s announcement from February 18th 2010 on the use of long acting beta-2 agonists in treatment of asthma].
    Kardos P; Berdel D; Buhl R; Criée CP; Freihorst J; Gillissen A; Karg O; Pfeifer M; Magnussen H; Rabe KF; Teschler H; Vogelmeier C; Welte T; Wettengel R; Worth H
    Pneumologie; 2010 Jun; 64(6):333-5. PubMed ID: 20533125
    [No Abstract]   [Full Text] [Related]  

  • 14. [Guidelines for the clinical management of COPD. Bronchodilatators].
    SPLF. Société de Pneumologie de Langue Française
    Rev Mal Respir; 2003 Jun; 20(3 Pt 2):S32-5. PubMed ID: 12910092
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-acting beta(2) agonists as potential option in the treatment of acute exacerbations of COPD.
    Cazzola M; Matera MG
    Pulm Pharmacol Ther; 2003; 16(4):197-201. PubMed ID: 12850121
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of arformoterol in the management of COPD.
    King P
    Int J Chron Obstruct Pulmon Dis; 2008; 3(3):385-91. PubMed ID: 18990965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise.
    Chang CL; Mills GD; McLachlan JD; Karalus NC; Hancox RJ
    Intern Med J; 2010 Mar; 40(3):193-200. PubMed ID: 19383058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD.
    Molimard M; Till D; Stenglein S; Singh D; Krummen M
    Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiotropium (Spiriva) for COPD.
    Med Lett Drugs Ther; 2004 May; 46(1183):41-2. PubMed ID: 15159658
    [No Abstract]   [Full Text] [Related]  

  • 20. Update on the management of COPD.
    Colby J; Goldman M
    Conn Med; 2009 Apr; 73(4):217-21. PubMed ID: 19413083
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.